Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma
- 13 December 2017
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 244 (3) , 367-379
Abstract
Oral squamous cell carcinoma (OSCC) has a very poor prognosis because of its highly invasive nature, and the 5‐year survival rate has not changed appreciably for the past 30 years. Although cylindromatosis (CYLD), a deubiquitinating enzyme, is thought to be a potent tumour suppressor, its biological and clinical significance in OSCC is largely unknown. This study aimed to clarify the roles of CYLD in OSCC progression. Our immunohistochemical analyses revealed significantly reduced CYLD expression in invasive areas in OSCC tissues, whereas CYLD expression was conserved in normal epithelium and carcinoma in situ. Furthermore, downregulation of CYLD by siRNA led to the acquisition of mesenchymal features and increased migratory and invasive properties in OSCC cells and HaCaT keratinocytes. It is interesting that CYLD knockdown promoted transforming growth factor‐β (TGF‐β) signalling by inducing stabilization of TGF‐β receptor I (ALK5) in a cell autonomous fashion. In addition, the response to exogenous TGF‐β stimulation was enhanced by CYLD downregulation. The invasive phenotypes induced by CYLD knockdown were completely blocked by an ALK5 inhibitor. In addition, lower expression of CYLD was significantly associated with the clinical features of deep invasion and poor overall survival, and also with increased phosphorylation of Smad3, which is an indicator of activation of TGF‐β signalling in invasive OSCC. These findings suggest that downregulation of CYLD promotes invasion with mesenchymal transition via ALK5 stabilization in OSCC cells. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- Kurozumi Medical Foundation
- Takeda Science Foundation
This publication has 56 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating AktNature Communications, 2012
- The Deubiquitinase CYLD Targets Smad7 Protein to Regulate Transforming Growth Factor β (TGF-β) Signaling and the Development of Regulatory T CellsJournal of Biological Chemistry, 2011
- TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancerNature Communications, 2011
- COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancerNucleic Acids Research, 2009
- CYLD negatively regulates cell‐cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulinThe EMBO Journal, 2009
- Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanomaJournal of Experimental Medicine, 2009
- TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4Cell, 2008
- Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathwaysProceedings of the National Academy of Sciences, 2007
- Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinomaGenes & Development, 2006